Latest ArticlesTo explore the therapeutic effect of acarbose combined with liraglutide in the treatment of early diabetic nephropathy(DN) and its influence on urinary microalbumin-to-creatinine ratio (UACR), serum creatinine(Scr), and estimated glomerular filtration rate(eGFR).
Patients with early DN admitted to Linquan county people's hospital from April 2022 to April 2025 were selected as the research subjects. Patients were divided into the experimental group(n=54) and the control group(n=52). The experimental group received treatment with acarbose combined with liraglutide, and the control group received treatment with liraglutide. Both groups received 8 weeks of treatment. The primary outcome was the overall effective rate, the secondary outcomes included the levels of UACR, Scr and eGFR before and after treatment, the improvement in blood glucose and blood lipids, and the incidence of adverse reactions.
After treatment, the total effective rate of the experimental group was higher than that of the control group(79.63% vs. 59.62%, P<0.05). After treatment, the UACR, Scr, fasting plasma glucose, 2-hour postprandial plasma glucose, glycosylated hemoglobin, total cholesterol, triglycerides, and low-density cholesterol levels in the experimental group were lower than those in the control group(P<0.05), and the eGFR level was higher than that in the control group(P<0.05).The incidence of adverse reactions in the experimental group was lower than that in the control group(9.26% vs. 11.54%), but there was no significant difference(P>0.05).
Acarbose combined with liraglutide can improve the clinical efficacy of DN, further improve UACR, Scr, and eGFR levels, lower blood glucose and lipid levels, and does not increase the risk of adverse events.
To analyze the efficacy of levocarnitine combined with benazepril for patients with essential hypertension(EH) and heart failure(HF), and its effects on exercise endurance and cardiovascular protection.
A total of 160 patients with EH and HF treated in our hospital from January 2022 to December 2024 were included.They were divided into the observation group and the control group by simple random sorting method, with 80 cases in each group. All patients received conventional treatment, and the control group was treated with benazepril, while the observation group was treated with levocarnitine as an adjunct to benazepril. The clinical efficacy, exercise endurance, cardiac function indicators, blood pressure, cardiovascular events, and safety were compared between the two groups.
After treatment, the total clinical effective rate of the observation group was higher than that of the control group(78.75% vs. 63.75%, P<0.05). After treatment, the peak oxygen consumption, maximum exercise duration, and six-minute walking test distance in both groups improved compared to pre-treatment(P<0.05), and the observation group was higher than the control group(P<0.05. After treatment, the left ventricular ejection fraction in both groups increased compared to pre-treatment(P<0.05), and the observation group was higher than the control group(P<0.05), the left ventricular end-diastolic diameter, left ventricular end-systolic diameter, and heart rate in both groups decreased compared to pre-treatment(P<0.05), and the observation group was lower than the control group(P<0.05). After treatment, the diastolic and systolic blood pressures in both groups decreased compared to pre-treatment(P<0.05), and the observation group was lower than the control group(P<0.05). During treatment, the total incidence of cardiovascular events in the observation group was lower than that in the control group(7.50% vs. 18.75%, P<0.05). There was no significant difference in the incidence of adverse drug reactions between the two groups during treatment(P>0.05).
Levocarnitine combined with benazepril is effective in treating EH with HF, and can further improve the exercise endurance and cardiac function of patients and protect the cardiovascular system.
To investigate the application of external fumigation and washing sitz bath combined with Qingre Jiedu formula and modified intersphincteric surgery in the treatment of high complex anal fistula.
A total of 86 patients with high-level complex anal fistulas admitted to Haian City Hospital of Traditional Chinese Medicine from January 2021 to January 2025 were included. The patients were randomly divided into groups at a 1:1 ratio using a computer-generated random number sequence. The random sequence was generated by independent statisticians and was distributed in a hidden manner through sequential numbering, opaque, and sealed envelopes. After enrollment, they were sequentially divided into the experimental group and the control group according to the order of enrollment, with 43 cases in each group. The control group received modified intersphincteric surgery treatment, while the experimental group additionally treated with external fumigation and washing sitz bath and Qingre Jiedu formula. The total effective rate, wound healing time, wound exudate volume, edema score, pain condition, anorectal dynamics, growth factor level, anal function, and the incidence of adverse reaction between the two groups were compared.
The total effective rate of the experimental group was higher than that of the control group(χ2=4.440,P=0.035). The wounds healing time in the experimental group was shorter than that in the control group(t=9.156,P<0.05). At 7 days, 14 days and 1 month after the operation, the wounds exudate volume in the experimental group were significantly lower than those in the control group(t=3.439、8.850、15.072,P<0.05). At 3 and 7 days after the operation, the edema score of the experimental group were significantly lower than those of the control group(t=2.303、2.945,P<0.05). At 3, 7, 14 days after the operation and 1 month later, the visual analogue pain score of the experimental group were significantly lower than those of the control group(t=8.232、11.104、13.751、10.267,P<0.05). Three months after the operation, the rectal compliance, rectal resting pressure, maximum rectal tolerance volume, epidermal growth factor, transforming growth factor β1, and vascular endothelial growth factor levels in the experimental group were all higher than those in the control group, while the rectal resting pressure and the scores of each item in the Wexner scale were lower than those in the control group(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).
External fumigation and washing sitz bath combined with Qingre Jiedu formula and modified intersphincteric surgery demonstrates significant efficacy in treating high complex anal fistula, promoting wound healing, reducing exudate and edema, alleviating pain, improving anorectal dynamics and growth factor levels, and enhancing anal function, with high safety.
Chimeric antigen receptor T cell therapy(CAR-T cell therapy) is a revolutionary cell-based immunotherapy technique that has initiated innovative exploration and clinical practice in pediatric medicine, bringing therapeutic hope to children with refractory and severe diseases. However, it may be accompanied by adverse reactions, which remains a key issue to be focused on in current research and clinical application. This paper comprehensively reviewed the latest research progress of CAR-T cell therapy at home and abroad, systematically summarized the application status of this therapy in pediatric hematological malignancies, solid tumors, and autoimmune diseases, and conducted in-depth analysis of its mechanism, providing a reference for clinical practice.
Juvenile idiopathic arthritis(JIA) is a common connective tissue disease in children, mainly characterized by chronic arthritis and often accompanied by systemic damage. The main therapeutic goals of JIA are to suppress symptoms and improve the quality of life of children. Conventional synthetic disease-modifying anti-rheumatic drugs, glucocorticoids, and nonsteroidal anti-inflammatory drugs are important components of JIA treatment, but long-term use is often associated with many adverse reactions. Since the 21st century, biological agents and small molecule targeted drugs have greatly improved the prognosis of children with JIA through precise regulation of immune responses. This article systematically reviewed the development history of JIA treatment regimens and the future research directions have been prospectively discussed, aiming to provide reference for clinical practice.
To systematically evaluate the current status, operational challenges, and service demands of pharmaceutical care clinics in maternal and child healthcare(MCH) institutions in Beijing, aiming to provide evidence-based references for optimizing pharmaceutical services for pregnant and lactating women and promoting the high-quality development in this specialized field.
A cross-sectional study was conducted using a questionnaire survey in 15 specialized MCH hospitals in Beijing. The survey investigated aspects including drivers and barriers to establishment, operational models, service scope, human resource allocation, and developmental bottlenecks.
Among the 15 surveyed institutions, 8(53.3%) had established pharmaceutical care clinics, mostly after 2021 and driven by national policies. The primary barrier for institutions without such clinics, was a shortage of qualified specialized pharmacists(71.4%). Services in established clinics were highly focused on medication safety counseling during pregnancy and lactation. Significant systemic bottlenecks were identified at the operational level: the lack of a unified national fee schedule for pharmaceutical services(4.8 points) and low pricing standards(4.7 points) were considered the primary challenges. The absence of a standardized training and certification system for specialized pharmacists(4.6 points) and a scarcity of senior, multi-skilled pharmacists(4.5 points) constrained team development. Internally, hospital management also included the difficulties such as heavy workloads and the lack of scientific performance evaluation and incentive mechanisms(both 4.6 points).
Pharmaceutical care clinics in Beijing's MCH institutions are in a preliminary, policy-driven stage of development, characterized by clear patient demand but uneven progress and prominent bottlenecks. It is imperative to establish a standardized training and certification system for specialized pharmacists, develop a rational pricing and health insurance reimbursement mechanism, and optimize internal operational management to foster professional, standardized, and sustainable development.
Topical preparations of traditional Chinese medicine(TCM) are effective for mild to moderate psoriasis(PsO) and atopic dermatitis(AD). In severe cases of PsO and AD, their adjunct use with conventional Western therapy can significantly delay disease recurrence. In PsO, they target multiple pathways such as the interleukin-17/helper T cell(Th)17 inflammatory axis and Janus kinase/STAT to exert anti-inflammatory effects, in AD, they block the Th2-type immune response and inhibit inflammation via the mitogen-activated protein kinase/nuclear factor-κB pathway.In vitiligo(Vit), TCM topical preparations are often combined with Western therapy to suppress Th1-type immunity and activate the microphthalmia associated transcription factor pathway, thereby promoting repigmentation of lesions.Furthermore, they can shorten the wound healing time in diabetic foot ulcer(DFU) by establishing a three-dimensional regulatory network involving "anti-inflammation-angiogenesis-collagen remodeling". However, current research is limited by low evidence levels and insufficient investigation into recurrence mechanisms. Therefore, this article systematically reviewed the clinical positioning of topical TCM preparations in inflammatory skin diseases such as PsO, AD, Vit, and DFU, as well as their advantages in delaying disease recurrence. It is anticipated that advanced clinical evidence and spatial transcriptomics technologies will be utilized to further explore their recurrence-delaying mechanisms and key targets, providing support for new drug development.
Influenza A virus(IAV) is a class of pathogenic viruses capable of causing seasonal epidemics and even global pandemics. It is characterized by a high mutation rate and strong transmissibility. Influenza A(commonly known as "flu A") is an acute respiratory infectious disease caused by IAV. Clinically, it is often accompanied by high fever, extreme fatigue, myalgia, arthralgia, and dry cough, posing a persistent threat to public health. Current antiviral drugs(such as neuraminidase inhibitors, RNA polymerase inhibitors, etc.) are limited by bottlenecks including a narrow treatment window, high drug resistance, and relatively high incidence of adverse reactions, thus urgent need for alternative or synergistic strategies. Traditional Chinese medicine has demonstrated unique advantages in the prevention and treatment of flu A, achieving remarkable effects in prevention, symptom improvement, and course shortening. This article systematically summarized the basic and clinical research evidence on the synergistic prevention and treatment of traditional Chinese medicine for flu A in recent years, aiming to provide references for subsequent research and clinical optimization of diagnosis and treatment protocols.
Inflammatory response is considered a key factor in the pathogenesis and progression of cardiovascular and cerebrovascular diseases, with pathological features mainly including cell necrosis, apoptosis, and mitochondrial dysfunction. Mitochondria serves as the cornerstone of cell metabolism, which mainly affects cells directly and indirectly by regulating energy metabolism, oxidative stress, autophagy, ferroptosis and apoptosis, promotes the abnormal activation of the immune system and accelerates the progress of inflammation, and plays an important role in the occurrence and development of cardiovascular and cerebrovascular related diseases. Traditional Chinese medicine possesses pharmacological activities that can repair mitochondrial function and inhibit inflammatory responses. It can significantly improve the inflammatory response in cardiovascular and cerebrovascular diseases by regulating mitochondria through multi-pathway, multi-target and multi-level regulation. Therefore, based on mitochondrial function, this paper reviewed the studies on mitochondrial protective function, maintain mitochondrial homeostasis, and mechanism for delaying disease progression of traditional Chinese medicine compounds, single flavor Chinese medicines, and traditional Chinese medicine extracts, aiming to provide a new basis for the prevention and treatment of cardiovascular and cerebrovascular related diseases.